Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing R...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 16, 2024

Five U.S. Cities Selected to Create Local Wealth Building Strategies Addressing Racial Wealth Equity • Harlem's Fashion Row is hosting its third annual Sustainability Forum, sponsored by H&M. The forum will give designers of co • Tekmetric Introduces Tire Suite Solutions to Streamline Tire Management Processes • Drama Notebook Reveals Website for Budget-Friendly, Royalty-Free Plays for Kids for Drama Education • P&G Professional Helps Restaurants Work Smarter, Not Harder with Dawn Professional Products They Can Trust to Clean More Eff • Stellus Capital Management, LLC Provides Unitranche Financing in Support of DW Healthcare Partners’ Investment in Med Lear • Pearson Awarded UK Government Contract for England’s National Curriculum Assessment (NCA) Tests • 4 Things Parents of Blind or Visually Impaired Youth and Teens Should Look for in a Summer Camp • Tyler Technologies Releases 2023 Corporate Responsibility Report • Grant Thornton names 51 Vets as its new Purple Paladin • California to Texas: The Top State-to-State Move in the U.S. • 2024 Upton Sinclair Memorial Lecture Examines Silicosis Epidemic Among Artificial-Stone Fabricators during AIHA Connect • Meijer Expands Great Lakes Stewardship Commitment with Donation to the Council of the Great Lakes Region Foundation • Barnes & Noble Education Announces Milestone Transactions to Significantly Strengthen Balance Sheet and Advance Industry Lea • Right at Home Partners with Free Wheelchair Mission to Give the Gift of Mobility to Kenyans • Bellco and Economic Literacy Colorado Celebrate National Financial Capability Month with Free "FUNancial $marts" Educational Boo • American Women Report Economic Stress, Worry about How They Will Afford Future Health Costs and Retirement • Emplifi Names Veteran Marketing Leader Susan Ganeshan as Its New CMO • CROWN ROYAL JOINS 2X ACM ENTERTAINER OF THE YEAR NOMINEE KANE BROWN AS THE OFFICIAL WHISKY OF THE 'IN THE AIR' TOUR • Denver Public Schools Selects CentralSquare’s Public Safety Pro Suite to Speed Response Times and Support Student and Staf

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. , June 10 /Businesswire/ - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units (“RSUs”) to nine new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $28.40 per share, Mirum’s closing trading price on June 9, 2023, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI^® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older, and in Europe for the same indication in patients two months of age and older.

Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months and older and in Europe in PFIC for patients two months and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.